Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

  • There is currently no data for BMK

Directorate Change

29 Nov 2023 07:01

RNS Number : 9803U
Benchmark Holdings PLC
29 November 2023
 

29 November 2023

 

Benchmark Holdings plc

("Benchmark" or the "Company")

Directorate Change

The Company is pleased to announce the appointment of Jonathan Esfandi as Non-Executive Director. Mr Esfandi is the founder and managing partner at JNE Partners LLP. 

Mr. Esfandi will act as shareholder representative of JNE Partners LLP, a significant shareholder of the Company, and therefore the Board has concluded that he is not an independent director. 

Laura Lavers, who joined the Board in November 2022, will retire from the Board as a Non-Executive Director with effect from today.

 

Peter George, Chairman, commented:

"We welcome Jonathan to the Board and look forward to working together. On behalf of the Board, I wish to thank Laura Lavers for her contribution over the past year."

The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in connection with the appointment of Jonathan to the Board of the Company:

Full Name: Jonathan Esfandi

Age: 49

Current Directorships: 

JNE PARTNERS LLP

JNE PARTNERS (UK) SERVICES LTD

Former Directorships (previous five years): None within the past five years

Beneficial interest in the equity securities of Benchmark Holdings plc: No direct beneficial interest. Funds managed by JNE Partners LLP have a holding of 169,263,811 shares in Benchmark

There is no further information required to be disclosed under Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

Enquiries

For further information, please contact:

Benchmark Holdings plc

Tel: 0114 240 9939

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

Deutsche Numis (Nominated Adviser and Broker)

Tel: 020 7260 1000

Freddie Barnfield, Duncan Monteith, Sher Shah

MHP

Tel: 020 3128 8004

Katie Hunt, Reg Hoare

benchmark@mhpgroup.com

 

Equity Development

Hannah Crowe

 

Tel: 020 7065 2692

 

About Benchmark

Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.

We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOADXBDBXGDDGXI
Date   Source Headline
23rd Jan 202411:20 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
23rd Jan 20247:00 amRNSNotice of Q1 Results
22nd Jan 20246:02 pmRNSRule 2.9 Announcement
22nd Jan 20245:14 pmRNSForm 8.3 - Benchmark Holdings Plc-Replacement
22nd Jan 20244:27 pmRNSForm 8.3 - Benchmark Holdings Plc
22nd Jan 20241:48 pmRNSForm 8.3 -Benchmark Holdings Plc
22nd Jan 20247:00 amRNSStrategic Review and Formal Sale Process
16th Jan 20245:30 pmRNSNotice of AGM - correction
9th Jan 20245:15 pmRNSPosting of Notice of AGM
12th Dec 20235:50 pmRNSNew Long Term Incentive Plan and PDMR Dealing
12th Dec 20231:54 pmRNSDirectorate Change
7th Dec 202312:00 pmRNSPublication of Annual Report and Notice of AGM
29th Nov 20237:01 amRNSDirectorate Change
29th Nov 20237:01 amRNSQ4 Results
29th Nov 20237:00 amRNSFull Year Results
6th Nov 202310:24 amRNSNotice of Q4 and Full Year Results
31st Oct 20237:00 amRNSTotal Voting Rights
10th Oct 202311:26 amRNSNew salmon broodstock licenses - correction
10th Oct 202310:06 amRNSGrant of two new salmon broodstock licenses
29th Sep 20237:00 amRNSTotal Voting Rights
21st Sep 20237:00 amRNSBlock Listing Six Monthly Return
31st Aug 20237:00 amRNSTotal Voting Rights
24th Aug 20237:00 amRNSQ3 Results
11th Aug 20237:00 amRNSNotice of Q3 Results
31st Jul 20237:00 amRNSTotal Voting Rights
30th Jun 20237:00 amRNSAppointment of Non-Executive Director
30th Jun 20237:00 amRNSTotal Voting Rights
31st May 20237:00 amRNSTotal Voting Rights
30th May 20233:30 pmRNSPCA Shareholding
30th May 202311:55 amRNSHolding(s) in Company
23rd May 20237:00 amRNSSecond Quarter and Interim results
5th May 20237:00 amRNSNotice of Q2 and Interim Results
28th Apr 20237:00 amRNSTotal Voting Rights
21st Apr 20231:00 pmRNSDirector Share Options
17th Apr 20237:00 amRNSDirectorate Change
12th Apr 20237:00 amRNSListing of Green NOK Bond
31st Mar 20237:00 amRNSTotal Voting Rights
21st Mar 20235:33 pmRNSShare Premium Reduction
21st Mar 20237:00 amRNSBlock Listing Six Monthly Return
17th Mar 20236:09 pmRNSHolding(s) in Company
2nd Mar 202311:12 amRNSDirector Dealings
28th Feb 20239:00 amRNSTotal Voting Rights
28th Feb 20237:00 amRNSQ1 Results
17th Feb 20237:00 amRNSAcquisition of remaining minority interest
16th Feb 20236:03 pmRNSResult of AGM
14th Feb 202311:45 amRNSNotice of Q1 Results
31st Jan 20237:00 amRNSTotal Voting Rights
27th Jan 20234:40 pmRNSSecond Price Monitoring Extn
27th Jan 20234:35 pmRNSPrice Monitoring Extension
17th Jan 20234:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.